Gan & Lee Pharmaceuticals.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
91.29 | 41.44 | 120.32% | 59.6 | +53.17% |
| P/S |
|
11.9 | 20.2 | -41.07% |
|
|
| P/BV |
|
2.89 | 3.68 | -21.41% |
|
|
| P/FCF |
|
-47.14 | 82.02 | -157.47% |
|
|
| Ev/Ebitda |
|
-22.38 | 16.62 | -234.63% |
|
|
| Ev/S |
|
6.34 | 25.64 | -75.27% |
|
|
| Ev/FCF |
|
-37.29 | 85.08 | -143.83% |
|
|
| E/P |
|
0.0163 | 0.0217 | -24.81% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-22.27 | 6.32 | -452.25% | 16.25 | -237.06% |
| ROE |
|
3.35 | 6.65 | -49.71% |
|
|
| ROA |
|
3.05 | 3.59 | -15.04% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
13.04 | -76.75 | -116.99% |
|
|
| ROCE |
|
0 | 19.43 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0446 | 0.7406 | -106.02% | -0.0446 | -0% |
| Nеt Debt/Ebitda |
|
0 | -0.1122 | -100% |
|
|
| Debt/Ratio |
|
0.0015 | 0.1008 | -98.56% |
|
|
| Debt/Equity |
|
0.003 | 0.212 | -98.58% |
|
|
| Debt/Net Income |
|
0.05 | 1.37 | -96.36% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.3991 | -100% | 0.4536 | -100% |
| Number of years of dividend growth |
|
0 | 1 | -100% | ||
| DSI |
|
0.5 | 0.6935 | -27.9% |
|
|
| Average dividend growth |
|
-14.58 | 3.04 | -579.48% |
|
|
| Average percentage for 5 years |
|
0.4536 | 1.4 | -67.54% |
|
|
| Average percentage for payments |
|
14.88 | 45.07 | -66.99% |
|
|
| Difference from average difference in sector |
|
-0.3991 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-9.91 | 23.95 | -141.38% | ||
| Growth impulse Ebitda in 5 years |
|
-150.15 | 12.85 | -1268.48% | ||
| Growth impulse Net Income in 5 years |
|
-70.87 | 62.77 | -212.9% | ||
| Growth impulse FCF in 5 years |
|
-159.36 | 30.35 | -625.07% | ||
| Growth impulse EPS in 5 years |
|
-75.22 | 82.9 | -190.74% |
IP Score
3.32/10
